Converting HR+ Breast Cancer Into an Individualized Vaccine
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Newly diagnosed post-menopausal women with clinical stage II-III, HR+HER2- breast cancer are
eligible to a randomized trial, concurrently open at five US academic institutions. Patients
receiving 4 months of standard neoadjuvant hormonal therapy with letrozole are randomly
assigned to one of 4 arms of a trial testing focal hypo-fractionated RT alone or with
immunotherapy combinations.
Phase:
Phase 2
Details
Lead Sponsor:
Weill Medical College of Cornell University
Collaborators:
Celldex Therapeutics Merck Sharp & Dohme Corp. United States Department of Defense